Navigation Links
Isis Pharmaceuticals Conference Call Notice
Date:6/30/2008

-- Tuesday, July 1, 2008

-- 10:00 a.m. EDT, 7:00 a.m. PDT

-- 877-548-7901

-- http://www.isispharm.com

SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals (Nasdaq: ISIS) will conduct a conference call at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, July 1, to discuss results of the TV-1102 clinical trial and the ATL / TEVA / Isis relationship.

-- ATL and TEVA announced clinical data on TV-1102 demonstrating positive disease benefit in patients with multiple sclerosis

-- Isis to received $1.3 million of ATL's $4 million milestone payment from TEVA
-- Isis may receive one third of up to $100 million in milestones

To view the press release

Please visit http://www.isispharm.com or http://www.antisense.com.au/_home.asp to view the release titled:

Teva Pharmaceuticals & Antisense Therapeutics Announce That ATL/TV 1102,

a Novel Drug for the Treatment of Relapsing Remitting Multiple Sclerosis

Demonstrated Significant Reduction in Disease Activity

To access this call via telephone

Please call 1-877-548-7901 in the United States, five to ten minutes prior to the call. You will be asked to provide your name and indicate that you wish to participate in the Isis Pharmaceuticals' conference call hosted by Dr. Stanley Crooke.

To access this call via internet:

Please go to the Isis website at http://www.isispharm.com five to ten minutes prior to the call and click on the Webcast icon on our Home Page.

This webcast will remain posted on Isis' website for a limited time.


'/>"/>
SOURCE Isis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... 8, 2017  StatLab Medical Products ("StatLab" ... manufacturer of diagnostic supplies for the anatomic ... & Company LP ("Cressey & Company"), a ... growth-focused investment in the Company. Cressey & ... from selling shareholder, Prairie Capital, L.P., with ...
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... two Phase 2 trials of its RSV F protein recombinant ... bearing age have been published in the journal ... been shared in prior scientific conferences). The Company previously announced ... 2014. Novavax is developing the RSV F Vaccine with the ...
(Date:6/5/2017)... , June 5, 2017 The ... brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded ... Cincinnati Enquirer . Results are based on an ... in organizational health and workplace improvement. The survey measures several ... ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... 2017 , ... The Pennsylvania Athletic Trainers’ Society’s (PATS) Annual ... Convention Center on June 8-10. The weekend consisted of many educational presentations, ... scholarship presentations, and professional networking. , On Friday June 9th, PATS hosted ...
(Date:6/23/2017)... ... 2017 , ... The Rhode Island Quality Institute (RIQI) and ... Dashboards, an innovative new service enabling healthcare providers to proactively coordinate care and ... Dashboards provide near real-time data about patients admitted to and/or discharged from acute ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or from ... how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, ... symptoms of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when ... read it, and some people don't like it at all. FindaTopDoc took a look ... , Erotic literature can give readers a taste of their deepest, darkest fantasies and ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia State ... 18 to 20. , The two-day conference is focused on advancing scientific knowledge ... improving patients’ lives and eliminating racial breast cancer-related disparities. The conference theme is ...
Breaking Medicine News(10 mins):